FDA Creates Exclusivity Board To Help Resolve Vexing Questions
Executive Summary
The board, housed within CDER, seeks to assure FDA makes consistent decisions on new chemical entity, new clinical trial and biologics exclusivity; FDA denied GSK’s request for NCE exclusivity for Veramyst and revoked Pfizer’s Torisel exclusivity.
You may also be interested in...
Forest’s Fetzima Will Test Enantiomer Exclusivity Policy Change
The antidepressant levomilnacipran, an enantiomer of Forest’s fibromyalgia drug Savella (milnacipran), could be the first product to take advantage of an FDA Amendments Act provision that allows enantiomers of previously approved drugs to qualify for five years of new chemical entity exclusivity.
Antibiotic Indications: Definition Of “Significant” Remains In FDA’s Hands After Vancocin Ruling
D.C. District Court Judge denies ViroPharma’s request for a preliminary injunction to require FDA to withdraw approval of three ANDAs, says company is unlikely to prevail in its suit challenging agency’s actions.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.